Sweeney & Michel’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sweeney & Michel’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$204K	Buy	+1,291	New	+$204K	0.05%	163

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Sweeney & Michel's XBI Position: Q3 2026 in Review

Sweeney & Michel opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q3 2026: 1,291 shares worth $204K. The stake represents 0.05% of the portfolio and ranks #163 among its holdings.

698 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Sweeney & Michel held 1,291 shares of State Street SPDR S&P Biotech ETF worth $204K as of Q3 2026.
State Street SPDR S&P Biotech ETF was a new Sweeney & Michel position in Q3 2026.
State Street SPDR S&P Biotech ETF made up 0.05% of Sweeney & Michel's portfolio in Q3 2026, its #163 holding.
698 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Sweeney & Michel's 13F filing for Q3 2026, filed 16 Oct 2026.